FindTrial
Sign In

To examine the visual function and thickness of macula to assess function of intravitreal injection of bevacizumab and triamcilone acetonide.

Efficacy and adverse effects of intravitreal triamcilone and bevacizumab on macular thickness and visual acuity in patients with diabetic macular edema.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/11/029064
Enrollment
60
Registered
2020-11-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H36- Retinal disorders in diseases classified elsewhere

Interventions

None listed

Sponsors

Father muller medical college
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Definite retinal thickening resulting from diabetic macular edema on clinical examination involving centre of macula. Diabetic macular edema confirmed via retinal thickness measured on optical coherence tomography.

Exclusion criteria

Exclusion criteria: Vitreous haemorrhage. History of any intraocular surgery/ photocoagulation within previous 3 months. History of periocular or intraocular drug injection. Any corneal opacity or cataract which affects pre operative OCT evaluation. Previous history of glaucoma treatment. Any other ocular comorbidities that has influence on macular thickness. Age less than 20 years

Design outcomes

Primary

MeasureTime frame
macular thickness visual acuityTimepoint: 6months—

Secondary

MeasureTime frame
visual acuityTimepoint: 6months—

Countries

India

Contacts

Public ContactNavya D

Father muller medical college

gonsalvessarita@gmail.com9740540741

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026